Federal
Newborn Screening Saves Lives Reauthorization Act of 2021
Source: Congress.gov ·
2,270 words in original text
Plain English summary not yet available
The full original text is available below. Check back soon as we process this bill.
IIB
117TH CONGRESS
1ST SESSION
H. R. 482
IN THE SENATE OF THE UNITED STATES
JUNE 24, 2021
Received; read twice and referred to the Committee on Health, Education,
Labor, and Pensions
AN ACT
To amend the Public Health Service Act to reauthorize cer-
tain programs under part A of title XI of such Act
relating to genetic diseases, and for other purposes.
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled,
2
VerDate Sep 11 2014
08:22 Jun 25, 2021
Jkt 019200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H482.RFS
H482
kjohnson on DSK79L0C42PROD with BILLS
2
HR 482 RFS
SECTION 1. SHORT TITLE.
1
This Act may be cited as the ‘‘Newborn Screening
2
Saves Lives Reauthorization Act of 2021’’.
3
SEC. 2. IMPROVED NEWBORN AND CHILD SCREENING AND
4
FOLLOW-UP FOR HERITABLE DISORDERS.
5
(a) PURPOSES.—Section 1109(a) of the Public
6
Health Service Act (42 U.S.C. 300b–8(a)) is amended—
7
(1) in paragraph (1), by striking ‘‘enhance, im-
8
prove or’’ and inserting ‘‘facilitate, enhance, im-
9
prove, or’’;
10
(2) by amending paragraph (3) to read as fol-
11
lows:
12
‘‘(3) to develop, and deliver to parents, families,
13
and patient advocacy and support groups, edu-
14
cational programs that—
15
‘‘(A) address newborn screening coun-
16
seling, testing (including newborn screening
17
pilot studies), follow-up, treatment, specialty
18
services, and long-term care;
19
‘‘(B) assess the target audience’s current
20
knowledge, incorporate health communications
21
strategies, and measure impact; and
22
‘‘(C) are at appropriate literacy levels;’’;
23
and
24
(3) in paragraph (4)—
25
VerDate Sep 11 2014
08:22 Jun 25, 2021
Jkt 019200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H482.RFS
H482
kjohnson on DSK79L0C42PROD with BILLS
3
HR 482 RFS
(A) by striking ‘‘followup’’ and inserting
1
‘‘follow-up’’; and
2
(B) by inserting before the semicolon at
3
the end the following: ‘‘, including re-engaging
4
patients who have not received recommended
5
follow-up services and supports’’.
6
(b) APPROVAL FACTORS.—Section 1109(c) of the
7
Public Health Service Act (42 U.S.C. 300b–8(c)) is
8
amended—
9
(1) by striking ‘‘or will use’’ and inserting ‘‘will
10
use’’; and
11
(2) by inserting ‘‘, or will use amounts received
12
under such grant to enhance capacity and infra-
13
structure to facilitate the adoption of,’’ before ‘‘the
14
guidelines and recommendations’’.
15
SEC. 3. ADVISORY COMMITTEE ON HERITABLE DISORDERS
16
IN NEWBORNS AND CHILDREN.
17
Section 1111 of the Public Health Service Act (42
18
U.S.C. 300b–10) is amended—
19
(1) in subsection (b)—
20
(A) in paragraph (5), by inserting ‘‘and
21
adopt process improvements’’ after ‘‘take ap-
22
propriate steps’’;
23
(B) in paragraph (7) by striking ‘‘and’’ at
24
the end;
25
VerDate Sep 11 2014
08:22 Jun 25, 2021
Jkt 019200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H482.RFS
H482
kjohnson on DSK79L0C42PROD with BILLS
4
HR 482 RFS
(C) by redesignating paragraph (8) as
1
paragraph (9);
2
(D) by inserting after paragraph (7) the
3
following:
4
‘‘(8) develop, maintain, and publish on a pub-
5
licly accessible website consumer-friendly materials
6
detailing—
7
‘‘(A) the uniform screening panel nomina-
8
tion process, including data requirements,
9
standards, and the use of international data in
10
nomination submissions; and
11
‘‘(B) the process for obtaining technical as-
12
sistance for submitting nominations to the uni-
13
form screening panel and detailing the in-
14
stances in which the provision of technical as-
15
sistance would introduce a conflict of interest
16
for members of the Advisory Committee; and’’;
17
(E) in paragraph (9), as redesignated—
18
(i) by redesignating subparagraphs
19
(K) and (L) as subparagraphs (L) and
20
(M), respectively; and
21
(ii) by inserting after subparagraph
22
(J) the following:
23
‘‘(K) the appropriate and recommended
24
use of safe and effective genetic testing by
25
VerDate Sep 11 2014
08:22 Jun 25, 2021
Jkt 019200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H482.RFS
H482
kjohnson on DSK79L0C42PROD with BILLS
5
HR 482 RFS
health care professionals in newborns and chil-
1
dren with an initial diagnosis of a disease or
2
condition characterized by a variety of genetic
3
causes and manifestations;’’; and
4
(2) in subsection (g)—
5
(A) in paragraph (1) by striking ‘‘2019’’
6
and inserting ‘‘2026’’; and
7
(B) in paragraph (2) by striking ‘‘2019’’
8
and inserting ‘‘2026’’.
9
SEC. 4. CLEARINGHOUSE OF NEWBORN SCREENING INFOR-
10
MATION.
11
Section 1112(c) of the Public Health Service Act (42
12
U.S.C. 300b–11(c)) is amended by striking ‘‘and supple-
13
ment, not supplant, existing information sharing efforts’’
14
and inserting ‘‘and complement other Federal newborn
15
screening information sharing activities’’.
16
SEC. 5. LABORATORY QUALITY AND SURVEILLANCE.
17
Section 1113 of the Public Health Service Act (42
18
U.S.C. 300b–12) is amended—
19
(1) in subsection (a)—
20
(A) in paragraph (1)—
21
(i) by striking ‘‘performance evalua-
22
tion services,’’ and inserting ‘‘development
23
of new screening tests,’’; and
24
(ii) by striking ‘‘and’’ at the end;
25
VerDate Sep 11 2014
08:22 Jun 25, 2021
Jkt 019200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H482.RFS
H482
kjohnson on DSK79L0C42PROD with BILLS
6
HR 482 RFS
(B) in paragraph (2)—
1
(i) by striking ‘‘performance test ma-
2
terials’’ and inserting ‘‘test performance
3
materials’’; and
4
(ii) by striking the period at the end
5
and inserting ‘‘; and’’; and
6
(C) by adding at the end the following:
7
‘‘(3) performance evaluation services to enhance
8
disease detection, including the development of tools,
9
resources, and infrastructure to improve data anal-
10
ysis, test result interpretation, data harmonization,
11
and dissemination of laboratory best practices.’’; and
12
(2) in subsection (b) to read as follows:
13
‘‘(b) SURVEILLANCE ACTIVITIES.—The Secretary,
14
acting through the Director of the Centers for Disease
15
Control and Prevention, and taking into consideration the
16
expertise of the Advisory Committee on Heritable Dis-
17
orders in Newborns and Children established under sec-
18
tion 1111, shall provide for the coordination of national
19
surveillance activities, including—
20
‘‘(1) standardizing data collection and reporting
21
through the use of electronic and other forms of
22
health records to achieve real-time data for tracking
23
and monitoring the newborn screening system, from
24
VerDate Sep 11 2014
08:22 Jun 25, 2021
Jkt 019200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\H482.RFS
H482
kjohnson on DSK79L0C42PROD with BILLS
7
HR 482 RFS
the initial positive screen through diagnosis and
1
long-term care management; and
2
‘‘(2) by promoting data sharing linkages be-
3
tween State newborn screening programs and State-
4
based birth defects and developmental disabilities
5
surveillance programs to help families connect with
6
services to assist in evaluating long-term outcomes.’’.
7
SEC. 6. HUNTER KELLY RESEARCH PROGRAM.
8
Section 1116 of the Public Health Service Act (42
9
U.S.C. 300b–15) is amended—
10
(1) in subsection (a)(1)—
11
(A) by striking ‘‘may’’ and inserting
12
‘‘shall’’; and
13
(B) in subparagraph (D)—
14
(i) by inserting ‘‘, or with a high prob-
15
ability of being recommended by,’’ after
16
‘‘recommended by’’; and
17
(ii) by striking ‘‘that screenings are
18
ready for nationwide implementation’’ and
19
inserting ‘‘that reliable newborn screening
20
technologies are piloted and ready for
21
use’’; and
22
(2) in subsection (b) to read as follows:
23
‘‘(b) FUNDING.—In carrying out the research pro-
24
gram under this section, the Secretary and the Director
25
VerDate Sep 11 2014
08:22 Jun 25, 2021
Jkt 019200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6201
E:\BILLS\H482.RFS
H482
kjohnson on DSK79L0C42PROD with BILLS
8
HR 482 RFS
shall ensure that entities receiving funding through the
1
program will provide assurances, as practicable, that such
2
entities will work in consultation with State departments
3
of health, as appropriate.’’.
4
SEC. 7. AUTHORIZATION OF APPROPRIATIONS FOR NEW-
5
BORN SCREENING PROGRAMS AND ACTIVI-
6
TIES.
7
Section 1117 of the Public Health Service Act (42
8
U.S.C. 300b–16) is amended—
9
(1) in paragraph (1)—
10
(A) by striking ‘‘$11,900,000’’ and insert-
11
ing ‘‘$31,000,000’’;
12
(B) by striking ‘‘2015’’ and inserting
13
‘‘2022’’; and
14
(C) by striking ‘‘2019’’ and inserting
15
‘‘2026’’; and
16
(2) in paragraph (2)—
17
(A) by striking ‘‘$8,000,000’’ and inserting
18
‘‘$29,650,000’’;
19
(B) by striking ‘‘2015’’ and inserting
20
‘‘2022’’; and
21
(C) by striking ‘‘2019’’ and inserting
22
‘‘2026’’.
23
VerDate Sep 11 2014
08:22 Jun 25, 2021
Jkt 019200
PO 00000
Frm 00008
Fmt 6652
Sfmt 6201
E:\BILLS\H482.RFS
H482
kjohnson on DSK79L0C42PROD with BILLS
9
HR 482 RFS
SEC. 8. INSTITUTIONAL REVIEW BOARDS; ETHICS GUID-
1
ANCE PROGRAM.
2
Section 12 of the Newborn Screening Saves Lives Re-
3
authorization Act of 2014 (42 U.S.C. 289 note) is amend-
4
ed to read as follows:
5
‘‘SEC. 12. INSTITUTIONAL REVIEW BOARDS; ETHICS GUID-
6
ANCE PROGRAM.
7
‘‘Research on nonidentified newborn dried blood spots
8
shall be considered secondary research (as that term is
9
defined in section 46.104(d)(4) of title 45, Code of Federal
10
Regulations (or successor regulations)) with nonidentified
11
biospecimens for purposes of federally funded research
12
conducted pursuant to the Public Health Service Act (42
13
U.S.C. 200 et seq.).’’.
14
SEC. 9. NAM REPORT ON THE MODERNIZATION OF NEW-
15
BORN SCREENING.
16
(a) STUDY.—Not later than 60 days after the date
17
of the enactment of this Act, the Secretary of Health and
18
Human Services shall seek to enter into an agreement
19
with the National Academy of Medicine (in this section
20
referred to as ‘‘NAM’’) (or if NAM declines to enter into
21
such an agreement, another appropriate entity) under
22
which NAM, or such other appropriate entity, agrees to
23
conduct a study on the following:
24
(1) The uniform screening panel review and
25
recommendation processes to identify factors that
26
VerDate Sep 11 2014
08:22 Jun 25, 2021
Jkt 019200
PO 00000
Frm 00009
Fmt 6652
Sfmt 6201
E:\BILLS\H482.RFS
H482
kjohnson on DSK79L0C42PROD with BILLS
10
HR 482 RFS
impact decisions to add new conditions to the uni-
1
form screening panel, to describe challenges posed
2
by newly nominated conditions, including low-inci-
3
dence diseases, late onset variants, and new treat-
4
ments without long-term efficacy data.
5
(2) The barriers that preclude States from add-
6
ing new uniform screening panel conditions to their
7
State screening panels with recommendations on re-
8
sources needed to help States implement uniform
9
screening panel recommendations.
10
(3) The current state of federally and privately
11
funded newborn screening research with rec-
12
ommendations for optimizing the capacity of this re-
13
search, including piloting multiple prospective condi-
14
tions at once and addressing rare disease questions.
15
(4) New and emerging technologies that would
16
permit screening for new categories of disorders, or
17
would make current screening more effective, more
18
efficient, or less expensive.
19
(5) Technological and other infrastructure
20
needs to improve timeliness of diagnosis and short-
21
and long-term follow-up for infants identified
22
through newborn screening and improve public
23
health surveillance.
24
VerDate Sep 11 2014
08:22 Jun 25, 2021
Jkt 019200
PO 00000
Frm 00010
Fmt 6652
Sfmt 6201
E:\BILLS\H482.RFS
H482
kjohnson on DSK79L0C42PROD with BILLS
11
HR 482 RFS
(6) Current and future communication and edu-
1
cational needs for priority stakeholders and the pub-
2
lic to promote understanding and knowledge of a
3
modernized newborn screening system with an em-
4
phasis on evolving communication channels and mes-
5
saging.
6
(7) The extent to which newborn screening
7
yields better data on the disease prevalence for
8
screened conditions and improves long-term out-
9
comes for those identified through newborn screen-
10
ing, including existing systems supporting such data
11
collection and recommendations for systems that
12
would allow for improved data collection.
13
(8) The impact on newborn morbidity and mor-
14
tality in States that adopt newborn screening tests
15
included on the uniform panel.
16
(b) PUBLIC STAKEHOLDER MEETING.—In the course
17
of completing the study described in subsection (a), NAM
18
or such other appropriate entity shall hold not less than
19
one public meeting to obtain stakeholder input on the top-
20
ics of such study.
21
(c) REPORT.—Not later than 18 months after the ef-
22
fective date of the agreement under subsection (a), such
23
agreement shall require NAM, or such other appropriate
24
entity, to submit to the Secretary of Health and Human
25
VerDate Sep 11 2014
08:22 Jun 25, 2021
Jkt 019200
PO 00000
Frm 00011
Fmt 6652
Sfmt 6201
E:\BILLS\H482.RFS
H482
kjohnson on DSK79L0C42PROD with BILLS
12
HR 482 RFS
Services and the appropriate committees of jurisdiction of
1
Congress a report containing—
2
(1) the results of the study conducted under
3
subsection (a);
4
(2) recommendations to modernize the proc-
5
esses described in subsection (a)(1); and
6
(3) recommendations for such legislative and
7
administrative action as NAM, or such other appro-
8
priate entity, determines appropriate.
9
(d) AUTHORIZATION OF APPROPRIATIONS.—There is
10
authorized to be appropriated $2,000,000 for the period
11
of fiscal years 2022 and 2023 to carry out this section.
12
Passed the House of Representatives June 23, 2021.
Attest:
CHERYL L. JOHNSON,
Clerk.
VerDate Sep 11 2014
08:22 Jun 25, 2021
Jkt 019200
PO 00000
Frm 00012
Fmt 6652
Sfmt 6201
E:\BILLS\H482.RFS
H482
kjohnson on DSK79L0C42PROD with BILLS
Important: This plain English summary was generated by AI and is provided for informational purposes only.
It is not legal advice. Always consult the official bill text on Congress.gov
or a qualified attorney for legal matters.